AP1897A - Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine. - Google Patents

Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.

Info

Publication number
AP1897A
AP1897A APAP/P/2003/002829A AP2003002829A AP1897A AP 1897 A AP1897 A AP 1897A AP 2003002829 A AP2003002829 A AP 2003002829A AP 1897 A AP1897 A AP 1897A
Authority
AP
ARIPO
Prior art keywords
vaccine
neisseria meningitidis
protein conjugate
polysaccharide
conjugate vaccine
Prior art date
Application number
APAP/P/2003/002829A
Other languages
English (en)
Other versions
AP2003002829A0 (en
Inventor
Robert P Ryall
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP1897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of AP2003002829A0 publication Critical patent/AP2003002829A0/xx
Application granted granted Critical
Publication of AP1897A publication Critical patent/AP1897A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
APAP/P/2003/002829A 2001-01-23 2002-01-22 Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine. AP1897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
PCT/US2002/001963 WO2002058737A2 (en) 2001-01-23 2002-01-22 Multivalent meningococcal polysaccharide-protein conjugate vaccine

Publications (2)

Publication Number Publication Date
AP2003002829A0 AP2003002829A0 (en) 2003-09-30
AP1897A true AP1897A (en) 2008-10-10

Family

ID=23001755

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002829A AP1897A (en) 2001-01-23 2002-01-22 Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.

Country Status (38)

Country Link
US (9) US8722062B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (3) EP2332581B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (6) JP2005504718A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (2) KR100947757B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN100556459C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AP (1) AP1897A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (2) AU2007216743A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (3) BE2012C050I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BRPI0206672B8 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2435681C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CR (1) CR7035A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (2) CY1113072T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (2) DK1355673T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (1) EA006947B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP034701A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (3) ES2544979T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (3) FR12C0072I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GE (1) GEP20053691B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20030598B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (2) HU230490B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (3) IL157060A0 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IS (1) IS6881A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (1) LT5177B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (1) LU92108I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LV (1) LV13128B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (2) MXPA03006561A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (1) NO20033816L (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (2) NZ622900A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
OA (1) OA12590A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL226184B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (2) PT2332581E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RO (1) RO122761B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI21352A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TN (1) TNSN03041A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UA (1) UA92579C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2002058737A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
YU (1) YU66103A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA200306176B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2544979T3 (es) 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Vacuna de conjugado de polisacárido-CRM197 meningocócica tri- o tetravalente
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
AU2003299501A1 (en) * 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
WO2004043489A1 (es) * 2002-11-14 2004-05-27 Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. Metodo de obtencion de vacunas conjugadas y composiciones vacunales que las contienen.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
WO2004080490A2 (en) * 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP2301571A1 (en) * 2003-05-07 2011-03-30 Sanofi Pasteur Inc. Tetravalent meningococcal vaccine with enhanced immunogenicity
EP2179729B1 (en) * 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP1644036A2 (en) * 2003-06-23 2006-04-12 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DK1740217T3 (da) * 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006026689A2 (en) * 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
WO2006034320A2 (en) * 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US8119146B2 (en) 2005-04-18 2012-02-21 Angelica Medina-Selby Expressing hepatitis B virus surface antigen for vaccine preparation
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
EP1993604B1 (en) 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
CA2646993C (en) 2006-03-22 2016-01-26 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
WO2011080595A2 (en) * 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
JP2013522287A (ja) 2010-03-18 2013-06-13 ノバルティス アーゲー 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン
EP4417216A1 (en) 2010-08-23 2024-08-21 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
US9057716B2 (en) * 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
ES2750366T3 (es) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA3066792C (en) 2012-03-09 2023-06-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
KR101742406B1 (ko) * 2012-08-16 2017-05-31 화이자 인코포레이티드 당접합 공정 및 조성물
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
SG11201506810RA (en) * 2013-03-18 2015-10-29 Glaxosmithkline Biolog Sa Method of treatment
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2015181834A2 (en) 2014-05-24 2015-12-03 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3258850B1 (en) 2015-02-20 2020-06-24 Bayer HealthCare LLC Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
PL3397319T3 (pl) 2015-12-30 2025-03-24 Ascendis Pharma A/S Automatyczny wstrzykiwacz z układem blokowania wkładu
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
US12119099B2 (en) 2018-09-12 2024-10-15 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
WO2020168146A1 (en) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
DK3937983T3 (da) 2019-12-17 2025-05-05 9286 3620 Quebec Inc Oral afliveringssystemer baserede på in situ-dannende protein/polysakkaridkoacervater
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025034954A1 (en) 2023-08-09 2025-02-13 Bayer Healthcare Llc Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045312A1 (en) * 1997-04-09 1998-10-15 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
DE3382737T2 (de) 1982-11-10 1994-05-19 Mitsubishi Heavy Ind Ltd Nickel-Chrom-Legierung.
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
DE3660966D1 (en) 1985-04-17 1988-11-24 Akzo Nv Method of applying a road marking composition
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE198834T1 (de) 1991-03-12 2001-02-15 Us Health Konjugate bestehend aus polysaccharid und protein
US5314811A (en) 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
CZ28694A3 (en) 1991-08-16 1994-05-18 Merck & Co Inc Process for preparing capsular polysaccharide free of lipid and endotoxin
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
DE122010000015I1 (de) * 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
PT658118E (pt) 1992-08-31 2002-05-31 Baxter Healthcare Sa Vacinas contra neisseria meningitidis do grupo c
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
DE69637597D1 (de) 1995-06-07 2008-08-21 Glaxosmithkline Biolog Sa Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
DK0833662T4 (da) 1995-06-23 2011-02-28 Smithkline Beecham Biolog Vaccinepræparat omfattende et Haemophilus influenza B-polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
NZ331578A (en) 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
DK0975790T3 (da) 1997-01-24 2005-01-24 Berna Biotech Ag Ny fremgangsmåde til isolering af polysaccharider
AU740784B2 (en) 1997-04-24 2001-11-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
WO1998054296A1 (en) 1997-05-28 1998-12-03 Chiron S.P.A. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
JP2002506448A (ja) 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
KR100641490B1 (ko) 1997-12-23 2006-10-31 박스터 헬쓰케어 에스.에이. 백신용도이거나 결합백신으로서 단백질에 결합되는 세균성 캡슐형 다당류의 추출 및 단리방법
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
HU226869B1 (en) 1999-02-01 2010-01-28 Eisai R & D Man Co Immunological adjuvant compound and composition containing thereof
IL145043A0 (en) * 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
EA006313B1 (ru) 2000-06-29 2005-10-27 Глаксосмитклайн Байолоджикалс С.А. Поливалентные иммуногенные композиции и способы их применения
ES2544979T3 (es) 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Vacuna de conjugado de polisacárido-CRM197 meningocócica tri- o tetravalente
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045312A1 (en) * 1997-04-09 1998-10-15 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIEBINK G S ET AL: THE JOURNAL OF INFECTIOUS DISEASES. (USA), Vol. 167, no. 2, 07/02/93, pp 347-355, XP008015590 � � *

Also Published As

Publication number Publication date
NO20033816D0 (no) 2003-08-27
US20130224241A1 (en) 2013-08-29
ZA200306176B (en) 2005-03-30
LT2003071A (en) 2004-08-25
US8999354B2 (en) 2015-04-07
BE2015C077I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2021-02-04
JP2016128526A (ja) 2016-07-14
OA12590A (en) 2006-06-08
FR15C0094I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2016-01-22
US8741314B2 (en) 2014-06-03
US20150174259A1 (en) 2015-06-25
US8722062B2 (en) 2014-05-13
US9844601B2 (en) 2017-12-19
ES2544979T3 (es) 2015-09-07
US20160000928A1 (en) 2016-01-07
IL157060A0 (en) 2004-02-08
EA006947B1 (ru) 2006-06-30
US20030068336A1 (en) 2003-04-10
JP2011140522A (ja) 2011-07-21
BRPI0206672B8 (pt) 2021-05-25
MXPA03006561A (es) 2004-10-15
LV13128B (en) 2004-07-20
CA2435681A1 (en) 2002-08-01
HUS1600040I1 (hu) 2019-05-28
PL226184B1 (pl) 2017-06-30
HRP20030598A2 (en) 2005-06-30
US20190060475A1 (en) 2019-02-28
IL225522A0 (en) 2013-06-27
RO122761B1 (ro) 2010-01-29
ES2388848T3 (es) 2012-10-19
FR22C1001I2 (fr) 2025-02-07
AU2010219288A1 (en) 2010-09-23
AP2003002829A0 (en) 2003-09-30
US10617766B2 (en) 2020-04-14
HUP0302999A2 (hu) 2003-12-29
CN100556459C (zh) 2009-11-04
US9173955B2 (en) 2015-11-03
UA92579C2 (ru) 2010-11-25
FR12C0072I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2013-01-04
KR100947757B1 (ko) 2010-03-18
FR22C1001I1 (fr) 2022-02-18
IL225522A (en) 2016-04-21
BE2022C502I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2023-04-12
YU66103A (sh) 2006-05-25
DK2332581T3 (en) 2015-10-05
TNSN03041A1 (en) 2005-12-23
LU92108I9 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2019-01-15
NZ602682A (en) 2014-05-30
PT2332581E (pt) 2015-10-16
EP2332581A1 (en) 2011-06-15
JP2014043474A (ja) 2014-03-13
KR20030084913A (ko) 2003-11-01
JP2014043475A (ja) 2014-03-13
CY2012030I2 (el) 2016-08-31
US8734813B2 (en) 2014-05-27
HU230490B1 (hu) 2016-08-29
AU2007216743A1 (en) 2007-10-04
JP2014065745A (ja) 2014-04-17
EP1355673B1 (en) 2012-05-30
JP2005504718A (ja) 2005-02-17
CY1113072T1 (el) 2015-08-05
EP2332581B1 (en) 2015-07-01
LT5177B (lt) 2004-11-25
PL373710A1 (en) 2005-09-05
NO20033816L (no) 2003-09-11
IL157060A (en) 2013-04-30
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
CY2012030I1 (el) 2015-08-05
DK1355673T3 (da) 2012-09-17
PT1355673E (pt) 2012-08-31
US20130216571A1 (en) 2013-08-22
ES2892316T3 (es) 2022-02-03
EP2957300A2 (en) 2015-12-23
US20140308311A1 (en) 2014-10-16
ECSP034701A (es) 2003-10-28
FR12C0072I2 (fr) 2013-11-01
KR20090029857A (ko) 2009-03-23
BE2012C050I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2021-03-23
NZ622900A (en) 2015-11-27
WO2002058737A2 (en) 2002-08-01
HRP20030598B1 (hr) 2013-05-31
FR15C0094I2 (fr) 2017-05-19
EP2957300B1 (en) 2021-07-14
EP2957300A3 (en) 2016-03-30
LU92108I2 (fr) 2013-01-29
CR7035A (es) 2008-11-25
JP5795721B2 (ja) 2015-10-14
IS6881A (is) 2003-07-22
EP1355673A2 (en) 2003-10-29
BRPI0206672B1 (pt) 2018-11-06
HUP0302999A3 (en) 2011-05-30
MX341760B (es) 2016-09-02
CA2435681C (en) 2011-06-21
SI21352A (sl) 2004-06-30
BR0206672A (pt) 2005-05-10
US10143757B2 (en) 2018-12-04
GEP20053691B (en) 2005-12-12
EA200300827A1 (ru) 2004-06-24
WO2002058737A3 (en) 2003-05-22
KR100947751B1 (ko) 2010-03-18
CN1610560A (zh) 2005-04-27

Similar Documents

Publication Publication Date Title
AP1897A (en) Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
TR201900418T4 (tr) Pnömokok polisakkarit konjugat aşısı.
WO2002091998A3 (en) Novel meningitis conjugate vaccine
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
MY145150A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2005526847A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
EA200801368A1 (ru) Конъюгатные вакцины
SI1755662T1 (sl) Kombinirani meningokokni konjugati s skupnim nosilnim proteinom
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
WO2006034320A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
MX2007007790A (es) Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente.
CY1116658T1 (el) Τρι- ή τετραδυναμο εμβολιο προϊοντος συζευξης μηνιγγοκοκκικου πολυσακχαριδιου-crm197